Effect of latent membrane protein 1 expression on overall survival in Epstein-Barr virus-associated cancers: a literature-based meta-analysis.
Effect of latent membrane protein 1 expression on overall survival in Epstein-Barr virus-associated cancers: a literature-based meta-analysis.
复制标题
潜伏膜蛋白 1 表达对 Epstein-Barr 病毒相关癌症总体生存的影响：基于文献的荟萃分析
DOI：
10.18632/oncotarget.4906
复制
发表时间：
2015-10-06
期刊：
影响因子：
--
通讯作者：
Ma J
中科院分区：
文献类型：
--
作者：
Chen YP;Zhang WN;Chen L;Tang LL;Mao YP;Li WF;Liu X;Zhou GQ;Sun Y;Kang TB;Zeng MS;Liu N;Ma J
潜伏膜蛋白1（LMP 1）是EB病毒（EBV）的主要转化癌蛋白。LMP 1在多种EBV相关癌症中频繁表达，包括鼻咽癌（NPC）、非霍奇金淋巴瘤（NHL）、霍奇金病（HD）和胃癌（GC）。然而，由于相互矛盾的结果，LMP 1表达对EBV相关癌症临床结局的预后价值仍不清楚。我们对32项研究共3752例患者进行了荟萃分析，以探讨EBV相关癌症中LMP 1表达与总生存期（OS）之间的关系。总体而言，LMP 1表达与OS较差显著相关（风险比，HR = 1.51，95%置信区间，CI，1.13-2.03），与癌症类型无关。进一步的分析表明LMP 1的表达与鼻咽癌患者的生存率相关（HR = 2.48，95% CI，1.77-3.47）和NHL患者（HR = 1.83，95% CI，1.07-3.15），但在HD患者（HR = 0.98，95% CI，0.60-1.62）或GC患者（HR = 0.70，95% CI，0.44-1.12）中没有。亚组分析表明，年龄和地理因素似乎对LMP 1阳性表达的HD患者的临床结局有影响。总之，LMP 1表达可作为NPC、NHL和某些HD患者的预后生物标志物。这些数据表明，靶向LMP 1的新疗法可能会改善EBV相关癌症患者的临床结局。
Latent membrane protein 1 (LMP1) is identified as the main transforming oncoprotein of Epstein-Barr virus (EBV). LMP1 is frequently expressed in a variety of EBV-associated cancers, including nasopharyngeal carcinoma (NPC), non-Hodgkin lymphoma (NHL), Hodgkin disease (HD), and gastric cancer (GC). However, due to conflicting results, the prognostic value of LMP1 expression on clinical outcomes in EBV-associated cancers remains unclear. We performed a meta-analysis on 32 studies with a total of 3752 patients to explore the association between LMP1 expression and overall survival (OS) in EBV-associated cancers. Overall, LMP1 expression was significantly associated with poorer OS (hazard ratio, HR = 1.51, 95% confidence interval, CI, 1.13–2.03), irrespective of cancer type. Further analyses showed that LMP1 expression correlated with poorer OS in NPC (HR = 2.48, 95% CI, 1.77–3.47) and NHL patients (HR = 1.83, 95% CI, 1.07–3.15), but not in HD patients (HR = 0.98, 95% CI, 0.60–1.62) or GC patients (HR = 0.70, 95% CI, 0.44–1.12). Subgroup analyses indicated that the age and geographical factors seemed to have an effect on the clinical outcomes of HD patients with positive LMP1 expression. In conclusion, LMP1 expression can be used as a prognostic biomarker in NPC, NHL, and certain HD patients. This data suggests that novel therapies targeting LMP1 may improve clinical outcomes for EBV-associated cancer patients.